This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alimera Sciences Reports Fourth Quarter 2010 Financial Results

Reiterates Positive 36-Month Results From the Completed Phase 3 FAME™ Study of ILUVIEN® in Patients With Diabetic Macular Edema

Cash, Cash Equivalents and Investments at December 31, 2010 Totaled $54.8 Million

ATLANTA, Feb. 10, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and year ended December 31, 2010.

"Our recently released 36-month data showed a consistent response rate of patients whose best corrected visual acuity improved by 15 or more letters from baseline at month 24 and month 36, with a peak rate of 31.4% in month 30. We believe these data demonstrate that ILUVIEN® can provide a long-term option for the treatment of diabetic macular edema (DME), for up to three years, and we look forward to continuing to work with the FDA toward the approval of ILUVIEN for the treatment of DME," said Dan Myers, president and chief executive officer of Alimera. "During the fourth quarter of 2010, we increased our pre-marketing budget in preparation for the commercial launch of ILUVIEN previously expected in the first half of 2011. Our team has many years of experience launching new pharmaceutical products and we are confident in our go-to-market strategy for a potential introduction later this year."

Alimera received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in the latter half of December 2010. The FDA issued the CRL to communicate its decision that the New Drug Application (NDA) for the investigational drug ILUVIEN could not be approved in its present form.

The NDA included data through month 24 of the study. No new clinical studies were requested by the FDA in the CRL. However, the FDA asked for analyses of the safety and efficacy data through the end of the FAME™ Study to further assess the relative benefits and risks of ILUVIEN. Alimera is currently preparing the analyses the FDA requested having completed the FAME Study and publicly released data on February 3, 2011. The FDA is also seeking additional information regarding controls and specifications concerning the manufacturing, packaging and sterilization of ILUVIEN, which Alimera is in the process of compiling.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.01 -1.20%
FB $118.06 0.54%
GOOG $695.70 0.48%
TSLA $226.77 -2.40%
YHOO $37.40 3.90%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs